08:00 AM EDT, 05/27/2025 (MT Newswires) -- Covalon Technologies ( CVALF ) on Tuesday said the latest results from a clinical study evaluating its VALGuard Vascular Access Line Guard will be presented at two scientific meetings in the fall. The results will also be presented in an academic journal in due course.

VALGuard is a transparent line guard designed to protect IV line connections and hubs from external contaminants. The study was a prospective pre- and post- intervention study of VALGuard across critical and acute care units focused on reducing Central Line-Associated Blood Stream Infections (CLABSIs).

"Blood streams infections are a serious, but largely preventable complication that tragically affect hundreds of thousands of patients each year, with a mortality rate estimated at 15% to 20%," said Dr. Kate Evely, vice president of clinical affairs for Covalon ( CVALF ). "Major hospitals all over the United States are adding VALGuard as an important part of their infection prevention program's toolkit to protect intravenous lines from gross contamination, a known source of infection."